LifeStance Health Group opened at $13.64, in line with its previous close of $13.64. In the last trading session, the stock traded between $13.32 and $13.76. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in LifeStance Health Group is now worth
$ 111.23
giving a profit of
$ 11.23 (11.23%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
88.89%
Hold
11.11%
Sell
0%
Markets Today
Today's Change
$-0.31 (-2.27%)
Day High
$13.76
Day Low
$13.32
Day Open
$13.64
Prev Close
$13.64
Volume
6,53,772
1W Return
6.03%
1M Return
12.02%
3M Return
22.78%
6M Return
79.34%
1Y Return
167.57%
Fundamentals
Market Cap ($ Mn)
5,092
PE Ratio
94.69
PB Ratio
3.18
PEG Ratio
-
ROE
0.65%
ROCE
1.26%
EPS (TTM)
$0.06
Investment Returns
1 Week
6.03%
1 Month
12.02%
3 Months
22.78%
6 Months
79.34%
9 Months
88.47%
Financials
Quarterly
All values in $ Mn
333.0
Mar 25
345.3
Jun 25
363.8
Sep 25
382.2
Dec 25
403.5
Mar 26
435.4
Jun 26
Updates
16Oct
LifeStance Health Group Q3FY26 Results: Earnings call scheduled for Nov 5
LifeStance Health Group will release Q3FY26 earnings on November 5, 2026. Conference call scheduled for 8:30 am ET with conference ID 3056663. Webcast and replay available via Investor Relations website. Company operates over 550 centers across 35 states.
14 days ago
2Sep
LifeStance Health Group to present at Jefferies, Morgan Stanley conferences
LifeStance CFO Ryan McGroarty presents at Jefferies Healthcare Conference on Sept 14. CEO Dave Bourdon presents at Morgan Stanley Healthcare Conference on Sept 15. Live webcasts available via investor relations website with replays posted later.
1mo ago
6Aug
LifeStance Health Q2 Results: EPS beats estimates, sales rise 26%
LifeStance Health Group reported Q2 EPS of $0.06, beating the $0.04 estimate by 50% and turning profitable from a previous loss. Sales rose 26.08% YoY to $435.354 million, also exceeding the $414.577 million estimate.
2mo ago
6Aug
LifeStance Health Q3 Results: Sales guidance beats estimates
LifeStance Health Group reports Q3 sales guidance of $420.000 million to $440.000 million, beating the $418.474 million analyst estimate. The forecast underscores strong revenue momentum and exceeds consensus expectations at both the low and high ends of the range.
2mo ago
6Aug
LifeStance Health raises FY26 sales guidance above estimates
LifeStance Health Group raised its FY2026 sales guidance to $1.685B-$1.725B, surpassing the $1.665B market estimate. The revision reflects strong underlying demand and operational execution in the behavioral health sector.
2mo ago
21Jul
Canaccord raises LifeStance price target to $13
Canaccord Genuity analyst Richard Close maintained a Buy rating on LifeStance Health Group and raised the price target to $13 from $11, signaling a positive outlook for the behavioral health services provider.
